ライブ

FierceBiotechImmunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails FierceBiotechEndologix acquires thrombectomy system from Surmodics Endpoints NewsParabilis reveals IPO plans the day after Regeneron deal as listings heat up Endpoints NewsGHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor FierceBiotechParabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push FierceBiotechPfizer furthers pneumococcal efforts, remains ‘comfortable’ taking on emerging threats: vaccine chief LabiotechEight Swedish companies spearheading the country’s biotech scene eLifeUncovering the electrical synapse proteome in retinal neurons via in vivo proximity labeling eLifeTwelve phosphomimetic mutations induce the assembly of recombinant full-length human tau into paired helical filaments IlluminaIllumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact - TradingView IlluminaIllumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact - PR Newswire Endpoints NewsTrumpRx adds hundreds of generic medicines to site

FierceBiotech 2026年5月20日

Pfizer furthers pneumococcal efforts, remains ‘comfortable’ taking on emerging threats: vaccine chief

After decades of developing vaccines to shield babies and adults from Streptococcus pneumonia infections, Pfizer is now taking another leap forward in its effor...

After decades of developing vaccines to shield babies and adults from Streptococcus pneumonia infections, Pfizer is now taking another leap forward in its efforts to protect against one of the bacteria’s most dangerous strains—all while keeping an eye on the world’s several emerging global health threats.